Ismael Bermejo-Álvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ismael Bermejo-Álvarez has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aránzazu Mediero
Joint and Bone Research Unit, Fundación Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz Universidad Autónoma de Madrid Madrid Spain
3 shared publications - Gabriel Herrero-Beaumont
Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Madrid, Spain
3 shared publications - Raquel Largo
Joint and Bone Research Unit, Rheumatology Department, Jimenez Diaz Foundation University Hospital, Madrid, Spain
3 shared publications - Alberto Irigaray-Moreno
Joint and Bone Research Unit, Rheumatology Department, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
1 shared publication - Cristina Villa-Gómez
Immunology Department, National Centre for Microbiology (CNM), Carlos III Health Institute (ISCIII), 28220 Madrid, Spain
1 shared publication - Cristina Vázquez
Joint and Bone Research Unit, Rheumatology Department, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 25 December 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
MSC administration resolves experimental acute gout increasing specialized pro-resolving mediators synthesis through a super-induction of prostaglandin E2
The resolution of inflammation is an active process triggered in the acute phase of inflammation and mainly directed by specialized pro-resolving mediators
- 25 December 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessMSC administration resolves experimental acute gout increasing specialized pro-resolving mediators synthesis through a super-induction of prostaglandin E2
The resolution of inflammation is an active process triggered in the acute phase of inflammation and mainly directed by specialized pro-resolving mediators
- Open Access
- 5 March 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (3) , 199-207
Aberrant anabolism hinders constructive metabolism of chondrocytes by pharmacotherapy in osteoarthritis
Osteoarthritis (OA) is a highly prevalent and disabling disease with an unmet therapeutic need. The characteristic cartilage loss and alteration of other joint structures result from a complex interaction of multiple risk factors, with mechanical overload consistently playing a central role. This overload generates an inflammatory response in the cartilage due to the activation of the innate immune response in chondrocytes, which occurs through various cellular mechanisms. Moreover, risk factors associated with obesity, being overweight, and metabolic syndrome enhance the inflammatory response both locally and systemically. OA chondrocytes, the only cells present in articular cartilage, are therefore inflamed and initiate an anabolic process in an attempt to repair the damaged tissue, which ultimately results in an aberrant and dysfunctional process. Under these circumstances, where the cartilage continues to be subjected to chronic mechanical stress, proposing a treatment that stimulates the chondrocytes’ anabolic response to restore tissue structure does not appear to be a therapeutic target with a high likelihood of success. In fact, anabolic drugs proposed for the treatment of OA have yet to demonstrate efficacy. By contrast, multiple therapeutic strategies focused on pharmacologically managing the inflammatory component, both at the joint and systemic levels, have shown promise. Therefore, prioritizing the control of chronic innate pro-inflammatory pathways presents the most viable and promising therapeutic strategy for the effective management of OA. As research continues, this approach may offer the best opportunity to alleviate the burden of this incapacitating disease.Cite this article: Bone Joint Res 2025;14(3):199–207.
- 5 March 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (3) , 199-207
Open AccessAberrant anabolism hinders constructive metabolism of chondrocytes by pharmacotherapy in osteoarthritis
Osteoarthritis (OA) is a highly prevalent and disabling disease with an unmet therapeutic need. The characteristic cartilage loss and alteration of other joint structures result from a complex interaction of multiple risk factors, with mechanical overload consistently playing a central role. This overload generates an inflammatory response in the cartilage due to the activation of the innate immune response in chondrocytes, which occurs through various cellular mechanisms. Moreover, risk factors associated with obesity, being overweight, and metabolic syndrome enhance the inflammatory response both locally and systemically. OA chondrocytes, the only cells present in articular cartilage, are therefore inflamed and initiate an anabolic process in an attempt to repair the damaged tissue, which ultimately results in an aberrant and dysfunctional process. Under these circumstances, where the cartilage continues to be subjected to chronic mechanical stress, proposing a treatment that stimulates the chondrocytes’ anabolic response to restore tissue structure does not appear to be a therapeutic target with a high likelihood of success. In fact, anabolic drugs proposed for the treatment of OA have yet to demonstrate efficacy. By contrast, multiple therapeutic strategies focused on pharmacologically managing the inflammatory component, both at the joint and systemic levels, have shown promise. Therefore, prioritizing the control of chronic innate pro-inflammatory pathways presents the most viable and promising therapeutic strategy for the effective management of OA. As research continues, this approach may offer the best opportunity to alleviate the burden of this incapacitating disease.Cite this article: Bone Joint Res 2025;14(3):199–207.
- Open Access
- 24 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (17) , 13181
Effects of Tofacitinib on Muscle Remodeling in Experimental Rheumatoid Sarcopenia
Sarcopenia is a frequent comorbidity of rheumatoid arthritis (RA). Clinical trials have shown that JAK inhibitors (JAKi) produce an asymptomatic increase in serum creatine kinase (CK) in RA, suggesting an impact on muscle. We evaluated the effect of JAKi in muscle remodeling in an experimental RA model. Antigen-induced arthritis (experimental RA, e-RA) was performed in 14 rabbits. Seven rabbits received tofacitinib (TOFA, orally 10 mg/kg/day). Animals were euthanized one day after the last ovalbumin injection, and muscles were prepared for histology, RT-PCR, and WB. C-reactive protein (CRP) and Myostatin (MSTN) serum concentration were determined by ELISA. Creatine and creatine kinase (CK) were analyzed. An increase in body weight as well as tibialis anterior cross-sectional area and diameter was observed in e-RA+TOFA vs. e-RA. e-RA decreased type II fibers and increased the myonuclei number, with all reverted by TOFA. TOFA did not modify CRP levels, neither did MSTN. TOFA significantly reduced IL-6, atrogin-1, and MuRF-1 compared with e-RA. e-RA+TOFA showed higher CK and lower creatine levels compared with e-RA. No differences in PAX-7 were found, while TOFA prevented the increase in MyoD1 in e-RA. Our model reflects the features of rheumatoid sarcopenia in RA. JAKi increased muscle mass through attenuating IL-6/JAK/STAT activation, decreasing atrogenes, and restoring muscle differentiation markers. These data together with an increase in CK support the role of CK as a valuable marker of muscle gain following JAKi treatment.
- 24 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (17) , 13181
Open AccessEffects of Tofacitinib on Muscle Remodeling in Experimental Rheumatoid Sarcopenia
Sarcopenia is a frequent comorbidity of rheumatoid arthritis (RA). Clinical trials have shown that JAK inhibitors (JAKi) produce an asymptomatic increase in serum creatine kinase (CK) in RA, suggesting an impact on muscle. We evaluated the effect of JAKi in muscle remodeling in an experimental RA model. Antigen-induced arthritis (experimental RA, e-RA) was performed in 14 rabbits. Seven rabbits received tofacitinib (TOFA, orally 10 mg/kg/day). Animals were euthanized one day after the last ovalbumin injection, and muscles were prepared for histology, RT-PCR, and WB. C-reactive protein (CRP) and Myostatin (MSTN) serum concentration were determined by ELISA. Creatine and creatine kinase (CK) were analyzed. An increase in body weight as well as tibialis anterior cross-sectional area and diameter was observed in e-RA+TOFA vs. e-RA. e-RA decreased type II fibers and increased the myonuclei number, with all reverted by TOFA. TOFA did not modify CRP levels, neither did MSTN. TOFA significantly reduced IL-6, atrogin-1, and MuRF-1 compared with e-RA. e-RA+TOFA showed higher CK and lower creatine levels compared with e-RA. No differences in PAX-7 were found, while TOFA prevented the increase in MyoD1 in e-RA. Our model reflects the features of rheumatoid sarcopenia in RA. JAKi increased muscle mass through attenuating IL-6/JAK/STAT activation, decreasing atrogenes, and restoring muscle differentiation markers. These data together with an increase in CK support the role of CK as a valuable marker of muscle gain following JAKi treatment.